Alnylam Pharmaceuticals Inc
ALNY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
45.1% downsideOvervalued by 45.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $40.32 Billion |
|---|---|
| Enterprise Value | $39.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.39 |
| Beta | 0.3 |
| Outstanding Shares | 132,893,000 |
Return
| Return on Equity | 53.68% |
|---|---|
| Return on Assets | 11.25% |
| Return on Invested Capital | 14.58% |
Valuation & Multiples
| P/E Ratio | 69.53 |
|---|---|
| PEG | -15.17 |
| Price to Sales | 9.14 |
| Price to Book Ratio | 36.57 |
| Enterprise Value to Revenue | 9.3 |
| Enterprise Value to EBIT | 72.35 |
| Enterprise Value to Net Income | 69 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 1.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4385▼ 23.36% |
|---|---|
| Total Calls | 1,296,588▼ 24.32% |
| Total Puts | 568,500▼ 50.63% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.23%▼ 1.47% |
|---|---|
| Total Invested | $42.44B▼ 17.59% |
| Investors Holding | 815▼ 76.00% |
ESG Score
No data
About Alnylam Pharmaceuticals Inc
CEO: John Maraganore Relevant Senate Committees
As the most powerful economic committee, it controls taxation (affecting Alnylam's profitability), trade policy (impacting global supply chains and market access), and critically, entitlement spending, including Medicare pricing and policies, which are major determinants of pharmaceutical revenue.
This committee directly allocates discretionary federal spending. Its subcommittees determine the specific funding levels for crucial agencies like the FDA, NIH, CMS (Medicare/Medicaid), and VA, profoundly impacting the regulatory environment, research funding, and market access for Alnylam's products.
This committee directly regulates the FDA, which is responsible for drug approval, and the NIH, which funds biomedical research. These functions are absolutely critical to Alnylam's product development, market entry, and long-term pipeline success.
Intellectual property laws (patents) are foundational to the pharmaceutical industry's business model. This committee's oversight of the DOJ, antitrust enforcement, and IP directly impacts Alnylam's ability to protect its innovations and navigate market competition.